Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild Impairment or Dementia in Primary Care
Study Details
Study Description
Brief Summary
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear. The sooner the patient is diagnosed, the sooner the patient will be in a position to prevent further deterioration.
A recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. It can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness.
Thus, the purpose of this study is to validate speech analysis AI models.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Outcome Measures
Primary Outcome Measures
- Vocal biomarkers to assess pre-post variability of normal, MCI and dementia at both point of the study. [Change from the baseline cognitive function at 9 months.]
Standard deviation of normal subjects, MCI and dementia to measure variations in language by using vocal biomarkers.
Secondary Outcome Measures
- Correlation between standard cognitive test (MMSE) and linguistic variables obtained by vocal biomarkers. [Through study completion, an average of 1 year.]
With a 95% confidence interval, the correlation between standard cognitive test (MMSE score) and each of the linguistic variables is quantified.
Other Outcome Measures
- Change of economic implications of accexible's use in a primary care center. [Through study completion, an average of 1 year.]
Percentage of expenditure when using the platform.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult patients 55+ years of age with suspected MCI or diagnosis of dementia and obtains a score greater than 20 on the MMSE.
-
Patients must have agreed to participate in the study and have voluntarily signed the informed consent.
-
(Healthy) Participants without a diagnosis neurological, or psychiatric disorders. Or taking medication that can affect cognitive abilities.
Exclusion Criteria
-
To have received a diagnosis of a significant psychiatric disorder or other cognitive impairment not due to neurodegeneration.
-
To have significant vision problems that would affect the ability to perceive visual stimuli.
-
To have significant hearing problems that would affect the ability to understand verbal cues.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | País Vasco | País Vasco | Spain |
Sponsors and Collaborators
- Accexible
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PS2020056